Tetra Bio-Pharma Inc. (TBPMF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tetra Bio-Pharma Inc. (TBPMF) trades at $0.0009. Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on cannabinoid-derived drug development for pain, inflammation, ophthalmology, and oncology. Market cap: $7.87M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for TBPMF: TBPMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TBPMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TBPMF: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Tetra Bio-Pharma Inc. (TBPMF) Healthcare & Pipeline Overview
Tetra Bio-Pharma Inc. develops cannabinoid-derived pharmaceuticals targeting unmet needs in pain management, oncology, and inflammation. With a focus on novel drug development, Tetra Bio-Pharma operates in the competitive biotechnology sector, pursuing clinical trials and strategic partnerships to advance its pipeline and commercialize innovative therapies.
What Is the Investment Thesis for TBPMF?
Tetra Bio-Pharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on cannabinoid-derived drugs offers potential for novel therapies in areas with unmet medical needs. Key value drivers include successful clinical trial outcomes for its drug candidates, particularly PLENITUDE and ARDS-003. The co-development agreement with Cellvera for ARDS-003 could provide a significant catalyst. However, the company's small market capitalization of $7.87M and negative P/E ratio of -0.21 indicate financial challenges. Investors should closely monitor clinical trial progress and regulatory approvals.
Based on FMP financials and quantitative analysis
TBPMF Key Highlights
Tetra Bio-Pharma is focused on cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology.
- The company's pipeline includes PLENITUDE for cancer-related pain and ARDS-003 for acute respiratory distress syndrome.
- Tetra Bio-Pharma has a co-development agreement with Cellvera Global Holdings LLC for ARDS-003.
- The company's market capitalization is $0.01 billion.
- Tetra Bio-Pharma operates with 33 employees.
Who Are TBPMF's Competitors?
TBPMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FWPAY Forward Pharma A/S | $300.00 | -25.09% | $7.45M | 45 |
| HBCNF HealthBeacon plc | $0.50 | +2269.67% | $8.44M | 44 |
| IMUN Immune Therapeutics, Inc. | $0.09 | -7.00% | $7.78M | 44 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TBPMF's Key Strengths?
Focus on cannabinoid-derived drugs.
- Pipeline of drug candidates targeting unmet medical needs.
- Co-development agreement for ARDS-003.
- Experienced management team.
What Are TBPMF's Weaknesses?
Small market capitalization.
- Negative P/E ratio.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
What Could Drive TBPMF Stock Higher?
Clinical trial results for PLENITUDE in cancer-related pain.
- Regulatory approval decisions for any of Tetra Bio-Pharma's drug candidates.
- Co-development progress with Cellvera Global Holdings LLC for ARDS-003.
- Expansion of research and development efforts in cannabinoid-derived drugs.
- Strategic partnerships and acquisitions to expand its product pipeline.
What Are the Key Risks for TBPMF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unsuccessful clinical trial outcomes for its drug candidates.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other pharmaceutical companies.
- Limited financial resources and the need to raise additional capital.
- Changes in government regulations regarding cannabis.
What Are the Growth Opportunities for TBPMF?
- ARDS-003 Co-Development: The co-development agreement with Cellvera Global Holdings LLC for ARDS-003 offers a significant growth opportunity. Combining ARDS-003 with Qifenda 400MG (Favipiravir) could create a more effective treatment for sepsis and acute respiratory distress syndrome. Successful clinical trials and regulatory approval could lead to substantial revenue generation.
- PLENITUDE for Cancer Pain: The development of PLENITUDE for cancer-related pain represents a key growth opportunity. Cancer pain management is a significant unmet medical need, and PLENITUDE's success in clinical trials could lead to regulatory approval and commercialization. The market for cancer pain therapeutics is substantial, offering a significant revenue stream for Tetra Bio-Pharma. The timeline for commercialization depends on successful clinical trial outcomes and regulatory approvals.
- PPP003 for Ophthalmic Conditions: Tetra Bio-Pharma's development of PPP003 for painful dry eye and uveitis pain offers another growth avenue. The market for ophthalmic therapeutics is expanding, driven by an aging population and increasing prevalence of dry eye disease. Successful clinical trials and regulatory approval of PPP003 could provide Tetra Bio-Pharma with a valuable product in this growing market. The timeline for commercialization depends on clinical trial results and regulatory approvals.
- Expansion of Cannabinoid Research: Tetra Bio-Pharma can expand its research and development efforts in cannabinoid-derived drugs to target additional therapeutic areas. This could involve developing new drug candidates for other indications or exploring novel delivery methods for existing drugs. Expanding its research pipeline could attract additional investment and partnerships, driving long-term growth. The market for cannabinoid-based therapies is expected to continue growing, presenting opportunities for Tetra Bio-Pharma to capitalize on its expertise.
- Strategic Partnerships and Acquisitions: Tetra Bio-Pharma can pursue strategic partnerships and acquisitions to expand its product pipeline and market reach. Partnering with other pharmaceutical companies or acquiring complementary businesses could accelerate its growth and diversify its revenue streams. These partnerships could provide access to new technologies, markets, and funding sources. The timeline for these opportunities depends on market conditions and the availability of suitable partners or acquisition targets.
What Are TBPMF's Competitive Advantages?
- Proprietary cannabinoid-derived drug formulations.
- Patents protecting its drug candidates.
- Clinical trial data demonstrating efficacy and safety.
- Strategic partnerships with other companies.
What Does TBPMF Do?
Tetra Bio-Pharma Inc., headquartered in Orléans, Canada, is a biopharmaceutical company dedicated to discovering and developing cannabinoid-derived drugs. The company's focus spans several therapeutic areas, including inflammation, pain, ophthalmology, and oncology. Tetra Bio-Pharma's pipeline includes several drug candidates in various stages of development. PLENITUDE is being developed for cancer-related pain in advanced cancer patients, while REBORN targets breakthrough cancer pain. Reduvo is intended to alleviate chemotherapy-induced nausea and vomiting, and ARDS-003 is under development for sepsis and the prevention of acute respiratory distress syndrome. SERENITY aims to treat cancer cachexia. Additionally, the company is developing PPP003 for painful dry eye and uveitis pain, and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma has a co-development agreement with Cellvera Global Holdings LLC for ARDS-003, combining it with Qifenda 400MG (Favipiravir), an antiviral drug. The company operates with 33 employees.
What Products and Services Does TBPMF Offer?
- Develop cannabinoid-derived drugs for inflammation.
- Develop cannabinoid-derived drugs for pain management.
- Develop cannabinoid-derived drugs for ophthalmology.
- Develop cannabinoid-derived drugs for oncology.
- Develop PLENITUDE to treat cancer-related pain.
- Develop REBORN for the treatment of breakthrough cancer pain.
- Develop Reduvo for chemotherapy-induced nausea and vomiting.
- Develop ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome.
How Does TBPMF Make Money?
- Develop and patent cannabinoid-derived drug formulations.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from health authorities.
- Partner with other companies for co-development and commercialization.
What Industry Does TBPMF Operate In?
Tetra Bio-Pharma operates in the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cannabinoid-derived drugs is growing, driven by increasing acceptance of medical cannabis and the potential for novel therapies. Competitors include both established pharmaceutical companies and smaller biotech firms focused on cannabinoid research. Tetra Bio-Pharma's success depends on its ability to successfully navigate the regulatory landscape, secure funding, and demonstrate the efficacy and safety of its drug candidates.
Who Are TBPMF's Key Customers?
- Patients suffering from cancer-related pain.
- Patients experiencing breakthrough cancer pain.
- Patients undergoing chemotherapy and experiencing nausea and vomiting.
- Patients at risk of or suffering from sepsis and acute respiratory distress syndrome.
Financial Health
Tetra Bio-Pharma Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TBPMF Valuation & Market Position
With a $7.87M market cap, Tetra Bio-Pharma Inc. sits in the micro-cap segment of the market.
Company Profile
Tetra Bio-Pharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Orléans, CA. The company is led by CEO Guy Chamberland Master Herbal. TBPMF has traded publicly since 2012.
TBPMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on cannabinoid-derived drugs.
- Pipeline of drug candidates targeting unmet medical needs.
- Co-development agreement for ARDS-003.
- Experienced management team.
Bear Case
- Small market capitalization.
- Negative P/E ratio.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
TBPMF Latest News
No recent news available for TBPMF.
TBPMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TBPMF.
Price Targets
Wall Street price target analysis for TBPMF.
TBPMF MoonshotScore
What does this score mean?
The MoonshotScore rates TBPMF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Guy Chamberland Master Herbal
CEO
Guy Chamberland is the CEO of Tetra Bio-Pharma Inc. His background includes experience as a Master Herbalist. Chamberland's expertise likely encompasses a deep understanding of botanical compounds and their potential therapeutic applications. His career has focused on the intersection of natural medicine and pharmaceutical development. Chamberland's background provides a unique perspective on the development of cannabinoid-derived drugs.
Track Record: Under Guy Chamberland's leadership, Tetra Bio-Pharma has focused on developing a pipeline of cannabinoid-derived drugs targeting various therapeutic areas. Key milestones include securing a co-development agreement with Cellvera Global Holdings LLC for ARDS-003 and advancing clinical trials for PLENITUDE. Chamberland has overseen the company's efforts to navigate the regulatory landscape and secure funding for its research and development programs.
TBPMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tetra Bio-Pharma Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, which increases the risk for investors. These companies are often speculative and may be subject to greater price volatility and potential for fraud compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in TBPMF.
- Low trading volume can lead to price volatility and difficulty in buying or selling shares.
- The OTC Other tier carries a higher risk of fraud and manipulation compared to major exchanges.
- TBPMF may not meet the minimum financial standards of higher-tier exchanges.
- The company's stock price may be highly speculative.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Check for any red flags or warning signs.
- The company has a pipeline of drug candidates in development.
- Tetra Bio-Pharma has a co-development agreement with Cellvera Global Holdings LLC.
- The company is focused on addressing unmet medical needs in pain management, oncology, and inflammation.
- The company has been in operation for several years.
- The company has a CEO with experience in the pharmaceutical industry.
Tetra Bio-Pharma Inc. Healthcare Stock: Key Questions Answered
What does Tetra Bio-Pharma Inc. do?
Tetra Bio-Pharma Inc. is a biopharmaceutical company focused on the discovery and development of cannabinoid-derived drugs. The company's pipeline includes drug candidates targeting various therapeutic areas, including pain management, oncology, inflammation, and ophthalmology. Tetra Bio-Pharma aims to address unmet medical needs by developing novel therapies based on cannabinoid science.
What are the main risks for TBPMF?
The main risks for Tetra Bio-Pharma Inc. include unsuccessful clinical trial outcomes, regulatory hurdles, competition from other pharmaceutical companies, limited financial resources, and changes in government regulations regarding cannabis. The company's success depends on its ability to successfully navigate these risks and demonstrate the efficacy and safety of its drug candidates. Investors should carefully consider these risks before investing in TBPMF.
What are the key factors to evaluate for TBPMF?
Evaluate TBPMF on fundamentals, analyst consensus, and risk factors. Tetra Bio-Pharma presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does TBPMF data refresh on this page?
TBPMF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TBPMF's recent stock price performance?
Tetra Bio-Pharma Inc. (TBPMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabinoid-derived drugs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TBPMF overvalued or undervalued right now?
Tetra Bio-Pharma Inc. (TBPMF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TBPMF before investing?
Before investing in Tetra Bio-Pharma Inc. (TBPMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding TBPMF to a portfolio?
Key strength of Tetra Bio-Pharma Inc. (TBPMF): Focus on cannabinoid-derived drugs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risks than exchange-listed stocks.